Low levels of serum adiponectin have been identified as a risk factor for developing type 2 diabetes (Li et al., 2009), hypertension (Adamczak et al., 2003; Kim et al., 2013), metabolic syndrome (Ryo et al., 2004), and coronary heart disease (CHD) (Frystyk et al., 2007). Here, ADIPOQ is linked to coronary artery disorder.